Biopharmaceutical CMO and CRO Market: Current Analysis and Forecast (2022-2028)
Emphasis on Source (Mammalian and Non-Mammalian); Services (Contract Manufacturing {Process Development, Fill & Finish Operations, Analytical & QC studies, Packaging}, Contract Research {Oncology, Inflammation & Immunology, Cardiology, Neuroscience, Others}); Product (Biologics {Monoclonal antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others} and Biosimilars); Region (North America, Europe, Asia-Pacific, Rest of the World); and Region/Country
The global biopharmaceutical CMO and CRO market is expected to grow at a significant rate of around 7% during the forecast period. Biopharmaceutical CRO and CMO have commonly used abbreviations for biopharmaceutical contract research organizations and contract manufacturing organizations. A biopharmaceutical CRO company provides clinical trial management services to biopharmaceutical and medical device manufacturers whereas CMOs are the organizations that manufacture active ingredients and final drug products. The rising prevalence of orphan and rare diseases along with the mergers of drug manufacturers with research companies provides a better platform for the growth of the biopharmaceutical CMO and CRO market. Furthermore, the surging incidences of chronic diseases increase the demand for appropriate drugs and treatment. For instance, as per CDC, 60 percent of Americans are suffering from at least one chronic disease which accounted for 197.7 million, and 40 percent of them have more than two diseases.
Boehringer Ingelheim International GmbH, Inc.; Lonza; Rentschler Biopharma SE; JRS PHARMA; ProBioGen AG; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.; TOYOBO CO., LTD.; Samsung Biologics; Thermo Fisher Scientific Inc; and AbbVie Inc are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.
Insights Presented in the Report
“Amongst source, mammalian category to witness higher CAGR during the forecast period”
Based on the source, the market has been bifurcated into mammalian and non-mammalian. Among them, the non-mammalian segment is expected to grow at a higher CAGR in the market. The frequent launch of services under this category along with the emergence of new market players is an important attributing factor in the growth of the segment. For instance, in August 2019, Sartorius Stedim Biotech (SSB), announced the launch of new services for mammalian cell bank manufacture under GMP conditions.
“Amongst services, the contract manufacturing to hold a dominant share in the market in 2020”
Based on the services, the market has been bifurcated into contract manufacturing and contract research. Among them, the contract manufacturing segment holds a dominant share of the market in 2020. The rising number of biopharmaceutical drug approvals and the presence of a large number of CMOs in the market are the important reasons for the substantial share of the contract manufacturing segments in the market.
“Amongst product, biosimilars segment to grow with a higher CAGR during the forecast period”
Based on the product, the market has been categorized into biologics and biosimilars. Among them, the biosimilars segment is anticipated to grow with a higher CAGR during the forecast period. With the rising number of patent expiration of various biopharmaceutical drugs in the upcoming future, rapid product launch, and the cost-effectiveness of biosimilar drugs are expected to drive segmental growth. For instance, in July 2021, Semglee became the first interchangeable biosimilar insulin product that is approved by the FDA.
“Asia-Pacific to witness the fastest growth in the market”
Asia-Pacific is anticipated to grow at the fastest growth during the forecast period. The major factors such as the availability of low labor and lower operating costs of manufacturing in the region are driving the market growth of the biopharmaceutical CMO and CRO market. Furthermore, the rapid development of the pharmaceutical and biopharmaceutical environment in the region is also an important factor for the growth of the market in Asia-Pacific.
Reasons to buy this report:
- The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
- The report presents a quick review of overall industry performance at one glance.
- The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
- Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
- The study comprehensively covers the market across different segments.
- Deep dive regional level analysis of the industry.
Customization Options:
The global biopharmaceutical CMO and CRO market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
Table of Contents
Research Methodology for the Biopharmaceutical CMO and CRO Market Analysis (2022-2028)
Analyzing the historical market, estimating the current market, and forecasting the future market of the global biopharmaceutical CMO and CRO market were the three major steps undertaken to create and analyze the adoption of biopharmaceutical CMO and CRO in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global biopharmaceutical CMO and CRO market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
Detail secondary study was conducted to obtain the historical market size of the biopharmaceutical CMO and CRO market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the biopharmaceutical CMO and CRO market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as source, service, and products. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the biopharmaceutical CMO and CRO markets. Further, we conducted factor analysis using dependent and independent variables such as the source, service, and products of the biopharmaceutical CMO and CRO. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the biopharmaceutical CMO and CRO market se across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global Biopharmaceutical CMO and CRO market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2028 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
- The industry’s market size, in terms of revenue (USD) and the adoption rate of the biopharmaceutical CMO and CRO market across the major markets domestically
- All percentage shares, splits, and breakdowns of market segments and sub-segments
- Key players in the global biopharmaceutical CMO and CRO market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global biopharmaceutical CMO and CRO market. Data was split into several segments & sub-segments post studying various parameters and trends in the source, service, and product in the global biopharmaceutical CMO and CRO market.
The main objective of the Global Biopharmaceutical CMO and CRO Market Study
The current & future market trends of the global biopharmaceutical CMO and CRO market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
- Analyze the current and forecast market size of the biopharmaceutical CMO and CRO market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
- Segments in the study include areas of source, service, and products.
- Define and analysis of the regulatory framework for the biopharmaceutical CMO and CRO industry.
- Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
- Analyze the current and forecast market size of the biopharmaceutical CMO and CRO market for the major region.
- Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World.
- Company profiles of the biopharmaceutical CMO and CRO market and the growth strategies adopted by the market players to sustain in the fast-growing market
- Deep dive regional level analysis of the industry
Related Reports
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
